

Accepted Manuscript

LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis

Hai Gao, Nana Gong, Zebin Ma, Xiaobo Miao, Jinchun Chen, Yan Cao, Gong Zhang



PII: S0141-8130(18)30642-1
DOI: doi:[10.1016/j.ijbiomac.2018.05.044](https://doi.org/10.1016/j.ijbiomac.2018.05.044)
Reference: BIOMAC 9645

To appear in:

Received date: 6 February 2018
Revised date: 1 May 2018
Accepted date: 8 May 2018

Please cite this article as: Hai Gao, Nana Gong, Zebin Ma, Xiaobo Miao, Jinchun Chen, Yan Cao, Gong Zhang , LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Biomac(2017), doi:[10.1016/j.ijbiomac.2018.05.044](https://doi.org/10.1016/j.ijbiomac.2018.05.044)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

lncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis

Hai Gao^{1,2&}, Nana Gong^{3&}, Zebin Ma^{4&}, Xiaobo Miao^{5&}, Jinchun Chen^{6*}, Yan Cao^{7*}, Gong Zhang^{8*}

1. Health and Human Service Department, Xiamen Xianyue Hospital, Fujian, China.

2. Affiliated Xianyue Hospital of Xiamen Medical College, Xiamen Medical College, Fujian, China.

3. Department of Laboratory, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangzhou China.

4. Second of Clinic Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.

5. Department of Chemo- and Radiation Oncology, NO.2 Hospital of Ningbo, Zhejiang, China.

6. Department of Rheumatism and Immunology, Affiliated Xiamen Hospital of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fujian, China.

7. Department of Emergency Medicine, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Hunan, China.

8. Department of Radiotherapy of People's Hospital of Shanxi Province, Taiyuan, China

& These authors contributed equally to this work.

*Corresponding to Jinchun Chen (E-mail: chenjinchun0592@163.com), Yan Cao (E-mail: viviancao1981@163.com) and Gong Zhang (E-mail: zhanggong7446@163.com).

Abstract

Recently, lncRNA ZEB2-AS1 was identified as a lncRNA that promoted cancer progression. However, the biological function and the underlying mechanism of ZEB2-AS1 in pancreatic cancer had not been reported. In the current study, we revealed that the expression level of ZEB2-AS1 was elevated in pancreatic cancer cell lines and tissues. ZEB2-AS1 inhibition decreased cell growth and invasion in pancreatic cancer. Mechanismly, ZEB2-AS1 exerted as a ceRNA and negatively regulated miR-204 expression. In addition, HMGB1 was identified as a down-stream target of miR-204. The miR-204/HMGB1 axis mediated ZEB2-AS1's effect on pancreatic cancer. Our findings revealed that lncRNA ZEB2-AS1 may be a candidate prognostic biomarker and a target for new therapies in pancreatic cancer patients.

Keywords: lncRNA ZEB2-AS1, miR-204, HMGB1, pancreatic cancer

1. Introduction

Pancreatic cancer is an extremely aggressive solid tumor and often develops local invasion and early metastasis. Notably, pancreatic cancer causes approximately 330000 deaths per year and pancreatic cancer patients have extremely poor prognosis and clinical outcome, with overall

Download English Version:

<https://daneshyari.com/en/article/8327171>

Download Persian Version:

<https://daneshyari.com/article/8327171>

[Daneshyari.com](https://daneshyari.com)